Fibroblast growth factor 21 (FGF21) is a liver-derived endocrine factor that stimulates glucose uptake in adipocytes. Here, we show that FGF21 activity depends on ␤Klotho, a single-pass transmembrane protein whose expression is induced during differentiation from preadipocytes to adipocytes. ␤Klotho physically interacts with FGF receptors 1c and 4, thereby increasing the ability of these FGF receptors to bind FGF21 and activate the MAP kinase cascade. Knockdown of ␤Klotho expression by siRNA in adipocytes diminishes glucose uptake induced by FGF21. Importantly, administration of FGF21 into mice induces MAP kinase phosphorylation in white adipose tissue and not in tissues without ␤Klotho expression. Thus, ␤Klotho functions as a cofactor essential for FGF21 activity.
Fibroblast growth factor 21 (FGF21) is a liver-derived endocrine factor that stimulates glucose uptake in adipocytes. Here, we show that FGF21 activity depends on ␤Klotho, a single-pass transmembrane protein whose expression is induced during differentiation from preadipocytes to adipocytes. ␤Klotho physically interacts with FGF receptors 1c and 4, thereby increasing the ability of these FGF receptors to bind FGF21 and activate the MAP kinase cascade. Knockdown of ␤Klotho expression by siRNA in adipocytes diminishes glucose uptake induced by FGF21. Importantly, administration of FGF21 into mice induces MAP kinase phosphorylation in white adipose tissue and not in tissues without ␤Klotho expression. Thus, ␤Klotho functions as a cofactor essential for FGF21 activity.
Klotho ͉ glucose ͉ adipocyte ͉ siRNA ͉ GLUT1 F ibroblast growth factor 21 (FGF21) was identified based on cDNA sequence homology to other FGFs (1) . Phylogenetic and structural analyses have assigned FGF21 to the FGF19 subfamily, which consists of FGF15 (the mouse ortholog of human FGF19), FGF19, FGF21, and FGF23 (2). The FGF19 subfamily members distinguish themselves from the other 15 FGFs in that they function in an endocrine fashion. FGF23 is secreted primarily from bone and acts on the kidney to inhibit phosphate reabsorption and vitamin D biosynthesis (3) (4) (5) . FGF15 is expressed by intestinal epithelium and is involved in the negative feedback regulation of bile acid synthesis in the liver (6) . FGF21 is expressed predominantly in the liver and has emerged as a metabolic regulator of glucose uptake in adipocytes during a search for novel agents with therapeutic potential to treat diabetes mellitus (7) . Indeed, administration of recombinant FGF21 lowered blood glucose levels in both obese mice and in diabetic mice. Furthermore, transgenic mice that overexpress FGF21 were hypoglycemic, sensitive to insulin, and resistant to diet-induced obesity (7) .
FGF21 can activate FGF receptors (FGFRs) and signaling molecules downstream, including FGFR substrate 2␣ (FRS2␣) and 44/42 MAP kinase (ERK1/2), in adipocytes (7) (8) (9) (10) . However, efforts to demonstrate a direct interaction between FGFRs and FGF21 have failed. In addition, various cell types of nonadipocyte origin including 3T3-L1 preadipocytes do not respond to FGF21 even though they express multiple FGFR isoforms (7) . Furthermore, BaF3 cells that overexpress FGFRs require suprapharmacological doses of FGF21 (200-800 nM) to produce a detectable mitogenic response (8) (9) (10) . These observations suggest that a cofactor(s) may be necessary for FGF21 to activate FGF signaling in adipocytes.
We and others identified Klotho, a single-pass transmembrane protein, as an essential cofactor for FGF23 to activate FGF23 signaling (11, 12) . Klotho was originally identified as a gene mutated in the klotho mouse that exhibited phenotypes resembling human premature-aging syndromes (13) . Major phenotypic overlaps were observed between Klotho-deficient mice and Fgf23 knockout mice (14, 15) , suggesting that Klotho and FGF23 may work in a common signal transduction pathway(s). Indeed, Klotho bound to multiple FGFRs and was necessary for FGF23 to bind FGFRs and activate FGF signaling in various types of cultured cells (11) . In this work we show that ␤Klotho, a Klotho family protein, functions as the cofactor required for FGF21 signaling.
Results and Discussion FGF21 Requires ␤Klotho to Activate FGF Signaling. Neither FGF21 nor FGF23 signaled in parental 293 cells as evidenced by lack of induction of phosphorylation of FRS2␣ and ERK1/2 ( Fig. 1) . We previously reported that ectopic overexpression of Klotho conferred responsiveness to FGF23 on 293 cells (11) . However, these Klotho-overexpressing cells did not respond to FGF21. In contrast, 293 cells expressing the related ␤Klotho protein acquired the ability to respond to FGF21 (Fig. 1) . We have shown that Klotho promotes FGF23 signaling by forming a ternary complex with FGF23 and FGFRs. Hence, we tested whether ␤Klotho plays a similar role in FGF21 signaling and forms a ternary complex with FGFRs.
␤Klotho Binds to Multiple FGFRs. The mammalian FGFRs are encoded by four distinct genes (FGFR1-FGFR4). The ectodomain of prototypical FGFRs consists of three Ig-like domains (D1-D3). A major alternative mRNA splicing event within the D3 of FGFR1-3 generates ''b'' and ''c'' isoforms, which have distinct FGF-binding specificities. An additional splicing event generates shorter FGFR1-3 isoforms lacking D1 and/or D1-D2 linker (9) . We transiently expressed different FGFR isoforms, depicted in Fig. 2 , and ␤Klotho in 293 cells and performed coimmunoprecipitation experiments. As shown in Fig. 2 , FGFR1c and FGFR4 precipitated ␤Klotho more efficiently than the other FGFRs. In contrast, the FGFR b isoforms did not pull down ␤Klotho under these experimental conditions. The preferential binding of ␤Klotho to FGFR c isoforms and FGFR4 is reminiscent of that of Klotho (11) .
Consistent with the strong interaction between ␤Klotho and FGFR1c and 4, ␤Klotho-FGFR1c and ␤Klotho-FGFR4 complexes were able to pull down FGF21 more efficiently than FGFRs alone and the other ␤Klotho-FGFR combinations, demonstrating that FGF21 requires ␤Klotho to bind to its cognate FGFRs stably (Fig. 3 ).
FGF21 Activity Depends on ␤Klotho Expression in Adipocytes.
Because FGF21 stimulates glucose uptake in differentiated adipocytes but not in preadipocytes (7), we reasoned that differentiated adipocytes and not preadipocytes express ␤Klotho. Indeed, we could not detect expression of ␤Klotho in preadipocytes, and furthermore, FGF21 failed to elicit a signal in these cells. The differentiated adipocytes, however, expressed ␤Klotho abundantly and responded robustly to FGF21 (Fig. 4A) . To substantiate further the dependence of FGF21 on ␤Klotho, we followed ␤Klotho expression as preadipocytes differentiated into adipocytes. Expression of ␤Klotho was detected as early as day 4 and continued to increase up to day 10. This temporal increase in ␤Klotho expression correlated with the ability of FGF21 to induce phosphorylation of FRS2␣ and ERK1/2 (Fig. 4B) . We also studied time course and dose response of FGF21-induced phosphorylation of FRS2␣ and ERK1/2. As shown in Fig. 4C , phosphorylation of FRS2␣ and ERK1/2 became evident at 3 and 5 min, respectively, and began to decline at Ϸ60 min after cell stimulation. Activation of FGF signaling was detectable with as low as 10 ng/ml (0.3 nM) FGF21 and saturated at 1,000 ng/ml (30 nM) FGF21. Lastly, we showed that endogenous ␤Klotho was able to pull down endogenous FGFR1c in differentiated adipocytes ( Fig. 4D ), indicating that ␤Klotho and FGFR1c form a complex under physiological conditions.
To provide more compelling evidence for the dependence of FGF21 signaling on ␤Klotho, we knocked down ␤Klotho expression in differentiated adipocytes by using an siRNA approach. Four independent siRNAs against different sequences in ␤Klotho suppressed activation of both FRS2␣ and ERK1/2 by FGF21 ( Fig. 5A ) and more importantly, abolished the effect of FGF21 on glucose uptake, indicating that ␤Klotho is essential for FGF21 to exert its metabolic activity on adipocytes (Fig. 5B) .
FGF21-induced glucose uptake in adipocytes is accompanied by up-regulation of glucose transporter 1 (GLUT1), which is known to regulate insulin-independent glucose uptake, but not glucose transporter 4 (GLUT4), which primarily contributes to insulin-dependent glucose uptake (7, 16) . Therefore, we determined GLUT1 and GLUT4 protein levels and found that the knockdown of ␤Klotho expression by siRNA also attenuated the ability of FGF21 to increase GLUT1 expression (Fig. 5C ). Thus, FGF21-␤Klotho signaling may be an important regulator in insulin-independent glucose uptake in adipocytes.
Insulin produced a greater increase in glucose uptake than FGF21 in 3T3-L1 adipocytes (data not shown). However, this finding may not necessarily mean that the impact of FGF21 on glucose metabolism is insignificant. The effect of FGF21 on glucose uptake becomes evident several hours after the stimulation and lasts for 24 h or longer (7) even though FGF21-induced Akt phosphorylation diminishes within 30 min in 3T3-L1 adipocytes (17) . In contrast, insulin-induced glucose uptake becomes evident within minutes after stimulation in these cells and attenuates within hours. The prolonged effect of FGF21 may influence glucose metabolism under physiological settings. In fact, FGF21 has a potent and sustained blood glucose-lowering effect when administered into diabetic and obese mice (7). These observations imply that FGF21 and insulin play distinct roles in the regulation of glucose metabolism: FGF21 induces a moderate and sustained increase in glucose uptake primarily through up-regulating GLUT1 expression, whereas insulin induces a strong and transient increase through promoting GLUT4 translocation from the intracellular pool to the plasma membrane.
To determine the dependence of FGF21 signaling on ␤Klotho in an in vivo setting, we injected FGF21 into mice and analyzed ERK1/2 phosphorylation in white adipose tissue (WAT), skeletal muscle, and kidney. Importantly, ␤Klotho was expressed in WAT but not in the skeletal muscle or kidney (Fig. 6A) . Consistent with the expression pattern of ␤Klotho, FGF21 induced ERK1/2 phosphorylation only in WAT (Fig. 6B) . As a control, injection of FGF23 into mice stimulated ERK1/2 phosphorylation only in the kidney where Klotho is expressed (Fig.  6C) . These data provide strong in vivo evidence for requirement of ␤Klotho and Klotho in FGF21-and FGF23-mediated tissue response, respectively.
The Klotho Gene Family Regulates Metabolic Activities of FGF Hormones. In this work, we show that ␤Klotho is expressed in adipocytes and enables FGF21 to bind to and activate its cognate FGFRs, leading to increased glucose uptake. This dependence of FGF21 on ␤Klotho represents the mechanism by which FGF21 acts specifically on adipose tissue. Similarly, we and others have demonstrated that Klotho enables FGF23 to bind and activate its cognate FGFRs. ␤Klotho was isolated based on cDNA sequence homology to Klotho (18). The ␤klotho gene encodes a single-pass transmembrane protein that shares 41% amino acid identity with Klotho and in addition to adipose tissue is also expressed in liver and pancreas. Mice deficient in ␤Klotho have overlapping phenotypes with mice lacking FGF15 or FGFR4 (6, 19, 20) . These phenotypes include increased bile acid synthesis and increased expression of two key bile acid synthases, CYP7A1 and CYP8B1, in the liver. Based on these genetic data and studies with primary hepatocytes, a model has emerged in which FGF15/FGF19 and FGFR4 and ␤Klotho cooperate to regulate bile acid synthesis negatively (6). Thus, it seems plausible that ␤Klotho acts also as a cofactor in FGF19/15 signaling.
In summary, the Klotho gene family may have evolved to confer tissue-specific bioactivity on FGF19 subfamily members. Further investigations on Klotho and ␤Klotho are expected to provide more insight into the molecular mechanisms by which the FGF19 subfamily regulates glucose metabolism, bile acid synthesis, and phosphate/vitamin D metabolism. FGF21 and FGF23 may play a pathogenetic role in human diseases such as diabetes, obesity, chronic kidney disease, and bone disorders. Klotho and ␤Klotho will be important targets of research when exploring therapeutic application of these endocrine FGFs.
Materials and Methods
Expression Vectors. Expression vectors for mouse FGFRs with a V5 epitope tag at the C terminus and murine FGF23 (R179Q) were described previously (11). The murine ␤Klotho cDNA was obtained by reverse transcriptase PCR from mRNAs of differ- entiated 3T3-L1 adipocytes. cDNA encoding murine FGF21 (IMAGE Clone; Invitrogen, Carlsbad, CA) or murine ␤Klotho was cloned into pEF1 expression vector (Invitrogen). Before subcloning, a FLAG epitope tag was added to the C terminus of ␤Klotho, and appropriate restriction enzyme sites were added to both ends by using synthetic oligonucleotides and PCR.
Cell Culture. The 3T3-L1 preadipocytes (American Type Culture Collection, Rockville, MD) were maintained in DMEM containing 10% calf serum (Mediatech, Herndon, VA). Differentiation to adipocytes was induced by culturing the cells for 2 days in differentiation medium [DMEM (American Type Culture Collection)/10% FBS/10 mM Hepes/MEM nonessential amino acids (NEAA)/penicillin/streptomycin (PC/SM) (all from Invitrogen)/2 M insulin/1 M dexamethasone/0.25 mM 3-isobutyl-1-methylxanthine (IBMX) (all from Sigma-Aldrich, St. Louis, MO)] and then culturing in differentiation medium without dexamethasone and IBMX for another 2 days. Thereafter, the medium was changed every 2 days with DMEM supplemented with 10% FBS/10 mM Hepes/NEAA/PC/SM. Accumulation of lipid droplets was observed in Ͼ95% of cells after 7 days, and the cells at day 7-10 were used for experiments.
Preparation of FGF21 and FGF23. Human recombinant FGF21 and FGF23 (R179Q) were expressed in Escherichia coli, refolded in vitro, and purified by affinity, ion-exchange, and size-exclusion chromatographies following a previously published protocol (21) . Serum-free conditioned medium containing murine FGF21 was collected from 293 cells transiently transfected with the FGF21 expression vector. The activity of FGF21 in the cell culture medium was determined by comparing its ability to induce ERK1/2 phosphorylation in differentiated 3T3-L1 adipocytes with that of recombinant human FGF21 of known concentration. The activity of murine FGF23 (R179Q) present in the cell culture medium was determined by using 293 cells stably expressing Klotho as described previously (11) . Conditioned medium with activity equivalent to that of 2,000 ng/ml (67 nM) recombinant human FGF21 and 300 ng/ml (10 nM) FGF23, respectively, was used to stimulate cultured cells. The same amount of serum-free conditioned medium from mocktransfected 293 cells was used as a negative control.
Immunoprecipitation and Immunoblotting. Subconfluent 293 cells were transfected with expression vectors for ␤Klotho and FGFRs 36 h before the experiments by using Lipofectamine as carrier (Invitrogen). The cells were lysed in buffer containing inhibitors for phosphatase and proteinase as described previously (22) . After saving a portion of each cell lysate sample for immunoblotting with anti-␤Klotho antibody, the cell lysates were incubated with anti-V5-agarose beads (Sigma-Aldrich) at 4°C for 3 h. The beads were washed four times with Tris-buffered saline containing 1% Triton X-100 (TBST); bead-bound proteins were eluted with Laemmli Expression of GLUT1 and GLUT4 was determined by immunoblot analysis by using the cell lysates from B. sample buffer, electrophoresed, and then transferred to Hybond C Extra membrane (Amersham Biosciences, Piscataway, NJ). The protein blots were incubated with anti-␤Klotho antibody (R&D Systems, Minneapolis, MN) or anti-V5 antibody (Invitrogen) followed by horseradish peroxidase-conjugated anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-mouse IgG (Amersham Biosciences). Chemiluminescence signals were developed with the SuperSignal West Dura system (Pierce, Rockford, IL). For detection of endogenous interaction between ␤Klotho and FGFR1c in differentiated 3T3-L1 adipocytes, cell lysate samples were incubated with anti-FGFR1c antibody (Santa Cruz Biotechnology) and protein G-Sepharose at 4°C for 2 h. The Sepharose beads were washed four times with complete lysis buffer and then twice with lysis buffer lacking Triton X-100. Bead-bound proteins were eluted with Laemmli sample buffer and subjected to immunoblot analysis by using anti-␤Klotho or anti-FGFR1c antibody.
FGF21 Pull-Down Experiments. Cell lysate samples prepared from 293 cells transfected with FGFR alone or from 293 cells cotransfected with FGFR and ␤Klotho were incubated with anti-V5-agarose beads at 4°C for 3 h. The beads were washed four times with TBST and then incubated with serum-free conditioned medium containing murine FGF21 at 4°C for 3 h. Thereafter, the beads were washed three times with KrebsRinger-Hepes buffer (118 mM NaCl/4.96 mM KCl/2.54 mM CaCl 2 /1.19 mM KH 2 PO 4 /1.19 mM MgSO 4 /20 mM Hepes, pH 7.4) containing 1% Triton X-100 followed by three washes with the same buffer lacking Triton X-100. Bead-bound proteins were eluted with Laemmli sample buffer and subjected to immunoblot analysis by using anti-V5 antibody, anti-␤Klotho antibody, or anti-mouse FGF21 antibody (R&D Systems).
Immunoblot Analysis of FGF Signaling. Cells cultured on multiwell plates were serum-starved overnight and then treated for 10 min either with human recombinant FGF21 or FGF23 (R179Q) or FGF1 (FGF1 was from Upstate Biotechnology, Lake Placid, NY). The cells were snap-frozen in liquid nitrogen and processed for immunoblot analysis by using anti-phospho-FRS2␣ antibody (Cell Signaling Technology, Beverly, MA), anti-phospho-44/42 MAP kinase (ERK1/2) antibody (Cell Signaling Technology), and anti-ERK antibody (Cell Signaling Technology) as described previously. Wild-type, 8-week-old, male inbred 129sv mice were administered either human recombinant FGF21 (0.3 g g Ϫ1 body weight) or FGF23 (R179Q, 0.1 g g Ϫ1 body weight) or vehicle (10 mM Hepes, pH 7.4/150 mM NaCl) by injection into the inferior vena cava. Perigonadal fat pads, kidneys, and hind limb muscles were excised 15, 17, and 19 min, respectively, after protein injection. The tissues were flash-frozen in liquid nitrogen and processed for immunoblot analysis by using anti-phospho-ERK, anti-ERK, and anti-actin (Chemicon International, Temecula, CA) antibodies. All animal experiments were approved by the Institutional Animal Care and Research Advisory Committee of the University of Texas Southwestern Medical Center at Dallas.
Knockdown of ␤Klotho by RNA Interference. 3T3-L1 adipocytes were transfected with siRNA duplexes by electroporation as described previously (23) . Briefly, differentiated 3T3-L1 adipocytes were harvested by using 0.5 mg/ml collagenase (SigmaAldrich), washed twice with PBS, and suspended in PBS (2 ϫ 10 7 per ml). The cells were mixed with 5 nmol per 10 7 cells of siRNA oligonucleotide against four different sequences in ␤Klotho (␤Klotho 1: sense, CGU GUU UGG UUA UAC GGC CUG GAC U; antisense, AGU CCA GGC CGU AUA ACC AAA CAC G; ␤Klotho 2: sense, CGC AGU UUA CCG AUC CUC ACC UGU A; antisense, UAC AGG UGA GGA UCG GUA AAC UGC G; ␤Klotho 3: sense, CAG UUU GCU CUG GAC UGG ACC UCU A; antisense, UAG AGG UCC AGU CCA GAG CAA ACU G; ␤Klotho 4: sense, GCG GAA GAC ACA GAC UGC ACC AUU U; antisense, AAA UGG UGC AGU CUG UGU CUU CCG C; Invitrogen) or nontargeting randomized sequences (control 1: sense, CAG UCG UGG UCG UCA CCA GUU UCU A; antisense, UAG AAA CUG GUG ACG ACC ACG ACU G; control 2: sense, GCG CAG AGA CAG UCA CCA CAA GUU U; antisense, AAA CUU GUG GUG ACU GUC UCU GCG C; Invitrogen), and electroporated with a gene pulser system at the setting of 0.18 kV and 960 F capacitance (Bio-Rad, Hercules, CA). Immediately after electroporation, the cells were mixed with complete medium and incubated for 10 min before reseeding onto collagen I-coated 12-well plates (Becton Dickinson Labware, Bedford, MA). Thirty to forty hours after transfection, the cells were serumstarved overnight and then stimulated with FGF21 or FGF1 and assayed for phosphorylation of FRS2␣ and ERK1/2 and for glucose uptake Glucose Uptake Assay. Differentiated 3T3-L1 cells transfected with either ␤Klotho siRNA or control siRNA were treated with 1 g/ml human recombinant FGF21 in DMEM supplemented with 0.1% free fatty acid (FFA)-free BSA (Sigma-Aldrich) for 18 h at 37°C. Unstimulated cells served as a negative control. The wells were washed with Krebs-Ringer-Hepes buffer supplemented with 0.1% FFA-free BSA and then incubated in the same buffer supplemented with 2-deoxy-D- [1- 3 H]glucose (0.4 Ci, 0.1 mM; Amersham Biosciences) for 1 h. The reaction was stopped by washing the cells twice with ice-cold PBS containing 20 M cytochalasin B (Sigma-Aldrich) followed by snap-freezing in liquid nitrogen. Cell-associated radioactivity was determined by liquid scintillation counting. Nonspecific deoxyglucose uptake was measured in the presence of 50 M cytochalasin B and subtracted from each sample to obtain specific uptake. A portion of each cell sample was saved immediately before the addition of D- [2- 
